24-Month Findings on Macitentan, Tadalafil for Pulmonary Arterial Hypertension, with Kelly Chin, MD

Published Date: 29 May 2025

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot